Li Du, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, highlights the potential of inhibition sumoylation to increase the cytotoxicity of existing anti-myeloma therapies. Dr Du explains that previous experiments have shown that inhibiting SUMO E1 potentiates the effect of lenalidomide and dexamethasone and immunotherapies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.